Floatz logo

Valaciclovir

Recurrent Ependymoma

Candel Therapeutics, Inc.Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

36 Active assets in the Recurrent Ependymoma cohort.

Asset / SponsorPhaseRating
Nivolumab
University of Florida
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB
Indoximod
Theodore S. Johnson
Phase 2B
ETOPOSIDE
Theodore S. Johnson
Phase 2B
Cyclophosphamide
Theodore S. Johnson
Phase 2B

View all 50 →

Same molecule, other indications

Valaciclovir is also rated in:

herpes simplex infectious diseaseDormant
BBB
Indicative ·
74 / 100
View asset →
schizoaffective disorderDormant
BB
Indicative ·
68 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →